|
Name |
Tryprostatin b
|
Molecular Formula | C21H25N3O2 | |
IUPAC Name* |
(3S,8aS)-3-[[2-(3-methylbut-2-enyl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC(=CCC1=C(C2=CC=CC=C2N1)C[C@H]3C(=O)N4CCC[C@H]4C(=O)N3)C
|
|
InChI |
InChI=1S/C21H25N3O2/c1-13(2)9-10-17-15(14-6-3-4-7-16(14)22-17)12-18-21(26)24-11-5-8-19(24)20(25)23-18/h3-4,6-7,9,18-19,22H,5,8,10-12H2,1-2H3,(H,23,25)/t18-,19-/m0/s1
|
|
InChIKey |
GLWYBXPXOSKQAW-OALUTQOASA-N
|
|
Synonyms |
tryprostatin b; triprostatin B; CHEBI:72760; 179936-52-8; (3S,8aS)-3-{[2-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; (-)-Tryprostatin B; CHEMBL36668; DTXSID40893998; (3S,8aS)-3-[[2-(3-methylbut-2-enyl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; C20512; Q27140126; (3S,8aS)-3-((2-(3-Methylbut-2-enyl)-1H-indol-3-yl)methyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
CAS | 179936-52-8 | |
PubChem CID | 9863281 | |
ChEMBL ID | CHEMBL36668 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 351.4 | ALogp: | 3.5 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 26 | QED Weighted: | 0.828 |
Caco-2 Permeability: | -4.855 | MDCK Permeability: | 0.00001200 |
Pgp-inhibitor: | 0.015 | Pgp-substrate: | 0.217 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.076 |
30% Bioavailability (F30%): | 0.485 |
Blood-Brain-Barrier Penetration (BBB): | 0.593 | Plasma Protein Binding (PPB): | 89.75% |
Volume Distribution (VD): | 0.982 | Fu: | 5.09% |
CYP1A2-inhibitor: | 0.226 | CYP1A2-substrate: | 0.297 |
CYP2C19-inhibitor: | 0.89 | CYP2C19-substrate: | 0.191 |
CYP2C9-inhibitor: | 0.482 | CYP2C9-substrate: | 0.899 |
CYP2D6-inhibitor: | 0.104 | CYP2D6-substrate: | 0.67 |
CYP3A4-inhibitor: | 0.839 | CYP3A4-substrate: | 0.439 |
Clearance (CL): | 6.444 | Half-life (T1/2): | 0.546 |
hERG Blockers: | 0.052 | Human Hepatotoxicity (H-HT): | 0.962 |
Drug-inuced Liver Injury (DILI): | 0.135 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.934 | Maximum Recommended Daily Dose: | 0.726 |
Skin Sensitization: | 0.46 | Carcinogencity: | 0.098 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.795 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001941 | 0.759 | D08VRO | 0.308 | ||||
ENC004933 | 0.690 | D09ZIO | 0.302 | ||||
ENC000981 | 0.690 | D01JGV | 0.296 | ||||
ENC003218 | 0.644 | D0U7GP | 0.296 | ||||
ENC004610 | 0.607 | D05MQK | 0.295 | ||||
ENC000975 | 0.607 | D0H4JM | 0.284 | ||||
ENC003217 | 0.588 | D0U7GK | 0.283 | ||||
ENC002519 | 0.566 | D02DMQ | 0.277 | ||||
ENC005484 | 0.537 | D01TSI | 0.271 | ||||
ENC000825 | 0.537 | D0Q5NX | 0.270 |